Hanmi Pharmaceutical Hits Upper Limit with ₩260 Billion Technology Export; Secondary Battery Strength Continues

This contract is for the HM17321 platform technology, with a specific contract value of ₩262.9 billion. The contract was signed with Genentech, a subsidiary of the Swiss pharmaceutical company Roche.

This technology's core function is to prevent muscle loss, and it is expected to enhance the sustainability of treatment effects through the application of long-acting platform technology.

Through this technology export contract, Hanmi Pharmaceutical will receive milestone bonuses at each clinical stage. These are success-based payments, disbursed as each development stage successfully progresses. Additionally, royalty revenues from the global rights transfer are expected to generate further income separate from the milestone bonuses.

Hanmi Pharmaceutical's upper limit is a natural outcome, and the upward trend is likely to continue until the end of this week. Investors are recommended to hold their shares until the end of this week. News of Hanmi Pharmaceutical's technology export is expected to positively impact the entire bio sector, potentially leading to a concurrent rise in other biotech stocks.

JPMorgan issued an 'overweight' opinion on Samsung SDI, suggesting that more shares could be purchased. The sustained rise in lithium carbonate prices also positively impacted the secondary battery sector. Additionally, issues related to battery shortages for data centers are also interpreted as contributing to the stock price increase of secondary battery-related companies.

The sharp rise in the secondary battery sector is also attributable to technical factors. Rebound buying flowed into stocks that had previously experienced excessive declines. In particular, as supply and demand normalized, short covering, or repurchases by short-selling forces, fueled the stock price increase. Analysts suggest that the strong buying pressure during the process of major short sellers buying back shares led to the sharp rise.